United Therapeutics' Orenitram delays disease progression in Phase III for PAH

United Therapeutics Corp. (NASDAQ:UTHR) said Orenitram treprostinil met the primary endpoint in the double-blind, international Phase III FREEDOM-EV trial in 690 pulmonary arterial hypertension (PAH) patients on background oral monotherapy. Thrice-daily oral Orenitram significantly delayed the time to first clinical worsening event by 26% vs. placebo (p=0.0391).

The company plans to submit the FREEDOM-EV data to FDA to support a label expansion for the drug, and will present detailed data at upcoming medical meetings...